← Leaderboards
Philip E Castle
American Society For Clinical Pathology
$1,304,418
Attributed
$1,580,487
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2011–20$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,681,880 · 10
CDC$540,000 · 1
By mechanism
U54$1,353,572 · 6
P20$1,177,226 · 3
U2G$540,000 · 1
R01$151,082 · 1
Top collaborators
- Kathryn M Anastos8 shared
- Leon Mutesa8 shared
- Kathleen Schmeler1 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsRwandaPublic HealthResourcesHuman PapillomavirusFundingProgramsPathogenesisMedicineResearch ActivityCaringResearch InfrastructureUniversitiesCancer PreventionAfricanAfricaBiometryCollaborationsFutureAids Related CancerLeadershipMilitary HospitalsAreaInjury
Grant awards (18)
A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical-Cancer Risk Reduction in HIV+ Women living in Mozambique$151,082
R01 · FY2020 · CA · contact PI
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium$300,792
U54 · FY2019 · CA
Core-002 (Cerv Cancer)$88,366
U54 · FY2019 · CA
Core-003 (HPV MSM)$76,911
U54 · FY2019 · CA
Core-005 (Shared Res)$70,819
U54 · FY2019 · CA
Core-001 (ADMIN CORE)$35,706
U54 · FY2019 · CA
Core-004 (Mentoring)$28,990
U54 · FY2019 · CA
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium$682,777
U54 · FY2018 · CA
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$231,282
P20 · FY2018 · CA · contact PI
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$204,891
P20 · FY2018 · CA · contact PI
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium$69,211
U54 · FY2018 · CA
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$43,091
P20 · FY2018 · CA · contact PI
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$16,700
P20 · FY2018 · CA · contact PI
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$340,631
P20 · FY2017 · CA · contact PI
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$290,860
P20 · FY2017 · CA · contact PI
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center$49,771
P20 · FY2017 · CA · contact PI
PEPFAR LABORATORY TRAINING PROJECT$300,000
U2G · FY2011 · PS · contact PI
PEPFAR LABORATORY TRAINING PROJECT$240,000
U2G · FY2011 · PS · contact PI